EUVIMEDEUVIMED entdecken
Open Access

Crystal structures of main proteases of SARS-CoV-2 variants bound to a benzothiazole-based inhibitor

Jiqing Luo, Weiwei Wang, Haihai Jiang, Wenwen Li, Pei Zeng, Jie Wang, Xuelan Zhou, Xiaofang Zou, Shenghui Chen, Qisheng Wang, Jin Zhang, Jian Li

Acta Biochimica et Biophysica Sinica · 2023

DOI: 10.3724/abbs.2023053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biochimica et Biophysica Sinica, 2023. Verfasst von Jiqing Luo und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, China. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Main protease (M pro) serves as an indispensable factor in the life cycle of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as well as its constantly emerging variants and is therefore considered an attractive target for antiviral drug development. Benzothiazole-based inhibitors targeting M pro have recently been investigated by several groups and proven to be promising leads for coronaviral drug development. In the present study, we determine the crystal structures of a benzothiazole-based inhibitor, YH-53, bound to M pro mutants from SARS-CoV-2 variants of concern (VOCs) or variants of interest (VOIs), including K90R (Beta, B.1.351), G15S (Lambda, C.37), Y54C (Delta, AY.4), M49I (Omicron, BA.5) and P132H (Omicron, B.1.1.529). The structures show that the benzothiazole group in YH-53 forms a C-S covalent bond with the sulfur atom of catalytic residue Cys145 in SARS-CoV-2 M pro mutants. Structural analysis reveals the key molecular determinants necessary for interaction and illustrates the binding mode of YH-53 to these mutant M pros. In conclusion, structural insights from this study offer more information to develop benzothiazole-based drugs that are broader spectrum, more effective and safer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansProtease InhibitorsCysteine EndopeptidasesAntiviral AgentsBenzothiazolesMolecular Docking Simulation

Stichwörter der Autor:innen

SARS-CoV-2YH-53benzothiazoleinhibitormain proteasevariant

Substanzen

Protease InhibitorsCysteine EndopeptidasesAntiviral AgentsBenzothiazoles

Autor:innen und Institutionen

  • College of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, China.
  • Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai 201204, China.
  • School of Basic Medical Sciences, Nanchang University, Nanchang 330031, China.
  • Shenzhen Crystalo Biopharmaceutical Co., Ltd., Shenzhen 518118, China.
  • Jiangxi Jmerry Biopharmaceutical Co., Ltd., Ganzhou 341000, China.
  • Nanchang Reproductive Hospital, Nanchang 330000, China.

Zitieren

APA

Luo, J., Wang, W., Jiang, H., Li, W., Zeng, P., Wang, J., Zhou, X., Zou, X., Chen, S., Wang, Q., Zhang, J., & Li, J. (2023). Crystal structures of main proteases of SARS-CoV-2 variants bound to a benzothiazole-based inhibitor. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2023053

Vancouver

Luo J, Wang W, Jiang H, Li W, Zeng P, Wang J, et al. Crystal structures of main proteases of SARS-CoV-2 variants bound to a benzothiazole-based inhibitor. Acta Biochimica et Biophysica Sinica. 2023. doi:10.3724/abbs.2023053

BibTeX
@article{Luo2023,
  author = {Luo, Jiqing and Wang, Weiwei and Jiang, Haihai and Li, Wenwen and Zeng, Pei and Wang, Jie and Zhou, Xuelan and Zou, Xiaofang and Chen, Shenghui and Wang, Qisheng and Zhang, Jin and Li, Jian},
  title = {Crystal structures of main proteases of SARS-CoV-2 variants bound to a benzothiazole-based inhibitor},
  journal = {Acta Biochimica et Biophysica Sinica},
  year = {2023},
  doi = {10.3724/abbs.2023053}
}
Kostenlos starten →